Compounds with a phosphonate group, i.e., \(-P(O)(OH)\) group attached directly to the molecule via a P-C bond serve as suitable non-hydrolyzable phosphate mimics in various biomedical applications. In principle, they often inhibit enzymes utilizing various phosphates as substrates. In this review we focus mainly on biologically active phosphonates that originated from our institute (Institute of Organic Chemistry and Biochemistry in Prague); i.e., acyclic nucleoside phosphonates (ANPs, e.g., adefovir, tenofovir, and cidofovir) and derivatives of non-nucleoside phosphonates such as 2-(phosphonomethyl) pentanedioic acid (2-PMPA). Principal strategies of their syntheses and modifications to prodrugs is reported. Besides clinically used ANP antivirals, a special attention is paid to new biologically active molecules with respect to emerging infections and arising resistance of many pathogens against standard treatments. These new structures include 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines or so-called “open-ring” derivatives, acyclic nucleoside phosphonates with 5-azacytosine as a base moiety, side-chain fluorinated ANPs, aza/deazapurine ANPs. When transformed into an appropriate prodrug by derivatizing their charged functionalities, all these compounds show promising potential to become drug candidates for the treatment of viral infections. ANP prodrugs with suitable pharmacokinetics include amino acid phosphoramidates, pivaloyloxymethyl (POM) and isopropoxycarbonyloxymethyl (POC) esters, alkyl and alkoxyalkyl esters, salicylic esters, (methyl-2-oxo-1,3-dioxol-4-yl) methyl (ODOL) esters and peptidomimetic prodrugs. We also focus on the story of cytostatics related to 9-[2-(phosphonomethoxy)ethyl]guanine and its prodrugs which eventually led to development of the veterinary drug rabacfosadine. Various new ANP structures are also currently investigated as antiparasitics, especially antimalarial agents e.g., guanine and hypoxanthine derivatives with 2-(phosphonoethoxy)ethyl moiety, their thia-analogues and N-branched derivatives. In addition to ANPs and their analogs, we also describe prodrugs of 2-(phosphonomethyl)pentanediolic acid (2-PMPA), a potent inhibitor of the enzyme glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA). Glutamate carboxypeptidase II inhibitors, including 2-PMPA have been found efficacious in various preclinical models of neurological disorders which are caused by glutamatergic excitotoxicity. Unfortunately its highly polar character and
1 INTRODUCTION

Phosphonates are compounds bearing a phosphonate (P(O)(OH)₂) group attached to the molecule via a P-C bond. They serve as non-hydrolyzable phosphate mimics in various biomedical applications. Usually, they inhibit enzymes utilizing phosphates as substrates. Some phosphonates occur in nature as natural phosphate antibiotics (e.g., fosfomycin). Some important synthetic phosphate-based drugs include bisphosphonates (for the treatment of osteoporosis) and the antivirals foscarnet and besifovir, and perzintofel (for the treatment of stroke). In this review we focus on two groups of biologically active phosphonates. The first originated from IOCB in Prague (acyclic nucleoside phosphonates; ANPs) and the second originated from a collaboration between IOCB and the Johns Hopkins Drug Discovery team [prodrugs of 2-(phosphonomethyl) pentanedioic acid (2-PMPA)].

2 ACYCLIC NUCLEOSIDE PHOSPHONATES (ANPs)

The common structural attribute of ANPs is a nucleobase attached to an aliphatic side chain and containing a phosphonomethyl residue. A methylene bridge between the phosphate moiety and the rest of the molecule excludes enzymatic dephosphorylation. The absence of the glycosidic bond increases resistance to chemical and biological degradation. Flexibility of acyclic chains enables these compounds to adopt conformations suitable for interaction with active sites of enzymes. Their biological activities are mostly antiviral but also cytostatic, immunomodulatory and antiparasitic. Their disadvantage are unfavourable pharmacological properties due to the presence of polar phosphonic acid functionality. ANPs are mostly impermeant to the cellular membrane and in addition, their absorption by gastrointestinal tract is limited which is disqualifying for oral application. To achieve oral bioavailability and intracellular delivery, their transformation to prodrugs is highly advisable.

More than three decades of systematic investigations of ANPs in our institute resulted in hundreds of their structural variations. Three of them are commercially available pharmaceuticals approved for the treatment of viral infections (cidofovir, adefovir and tenofovir). The mentioned compounds represent three different types of ANPs: HPMP derivatives, i.e., (S)-3-hydroxy-2-(phosphonomethoxy)propyl derivatives (e.g., (S)-HPMPC, cidofovir), PME derivatives, i.e., 2-(phosphonomethoxy)ethyl derivatives (e.g., PMEA, adefovir) and PMP derivatives, i.e., (R)-2-(phosphonomethoxy)propyl derivatives [e.g., (R)-PMPA, tenofovir]. This large topic became a subject of many reviews, especially by Antonín Holý and Erik De Clercq (Holý, 2003; De Clercq and Holý, 2005; De Clercq, 2007; De Clercq, 2011; De Clercq, 2013).

Syntheses of acyclic nucleoside phosphonates (ANPs) are based on several alternative approaches: 1) preparation of N-(hydroxyalkyl) derivatives of purine or pyrimidine bases followed by introduction of the phosphonomethyl residue, 2) alkylation of the nucleobase with an appropriate synthetic precursor, usually dialkyl ester of phosphonmethoxyalkyl halide or tosylate, 3) ring-closure reactions of some aminoalkylphosphonates forming appropriate heterocyclic base moieties (preparation ofaza and deazapurine ANPs) and 4) transformation of reactive functional groups at the side chain or in the heterocyclic base in a previously prepared phosphate (Holý, 2003).

2.1 Acyclic Nucleoside Phosphonate Drugs and Drug Candidates. Synthesis, Clinical Applications and Current Topics in Their Research

2.1.1 Synthesis of (S)-HPMP Derivatives

Preparation of (S)-HPMP derivatives (HPMPC, HPMPA, HPMPDAP, HPMP-5azaC) mostly utilizes the first approach: base catalysed nucleophilic opening of the oxirane ring in (S)-2-(trityloxyethyl)oxirane or (S)-glycidol butyrate with appropriate nucleobase (Figure 1). Thus created 3-O-substituted (S)-2,3-dihydroxypropyl derivatives are then treated with disopropyl tosloxymethane phosphonate and finally deprotected. Preparation of disopropyl tosloxymethanol phosphonate consists in the treatment of disopropyl phosphate with paraformaldehyde and triethylamine followed by tosylation (Holý, 1993). The alternative way is introduction of phosphonemethyl ether group using disopropyl bromomethylphosphonate (Göbel et al., 1992; Holý, 2005; Oh and Hong, 2008).

2.1.2 Cidofovir and its Prodrugs

Cidofovir has unique activity against practically all DNA viruses. Intracellularly, it is converted to cidofovir diphosphate which suppresses virus replication selectively by competitive inhibition of viral DNA polymerase. Incorporation of the drug disrupts further chain elongation. Under the brand name Vistide™, cidofovir was approved for the treatment of cytomegalovirus retinitis in AIDS patients (Plosker and Noble, 1999; Drugs.com, 2000).

Keywords: acyclic nucleoside phosphonates, antivirals, prodrugs, protides, GCPII, prostate-specific membrane antigen, FOLH1, 2-PMPA
Off label it is used for the treatment of severe cases of papillomatoses (Gi et al., 2012), progressive multifocal leukoencephalopathy (Andrei et al., 2015), adenovirus infections (Neofytos et al., 2007) and poxvirus infections, e.g., recalcitrant molluscum contagiosum and orf in immunocompromised patients (Cundy, 1999; Andrei and Snoeck, 2010). In justified cases, it was exceptionally applied also to immunocompetent pediatric patients with very complicated adeno-, polyoma- or cytomegalovirus infections (Neant et al., 2018; Alcamo et al., 2020).

Application of cidofovir is possible only intravenously and its bioavailability is very low. More than 90% of its intravenous dose is excluded unchanged by kidney. Nephrotoxicity of the cidofovir can be partially overcome by the pre-treatment with the nephroprotective drug probenecid (Lacy et al., 1998; Wolf et al., 2003).

To improve pharmacokinetic properties of cidofovir, various prodrugs are being investigated. So far the most important prodrugs are alkoxyalkyl esters (Kern et al., 2002; Beadle et al., 2002; Ruiz, 2011). They can be prepared by alkylation of N,N-dicyclohexyl-4-morpholinocarboxamidinium salt of cyclic cidofovir (cHPMPC) with appropriate alkoxyalkyl bromides (Figure 2) (Beadle et al., 2002; Kern et al., 2002) or condensation of cHPMPC with alkoxyalcohols under Mitsunobu conditions (Method 2) (Ruiz, 2011). Thus formed esters of cyclic HPMPC are subsequently cleaved to corresponding monoesters by the heating with aqueous sodium hydroxide. The method is applicable also for various other phosphonates (not only in the HPMP series) (Hostetler, 2009). Hexadecyloxypropyl (HDP) ester of cidofovir (Brincidofovir, CMX001) was being developed by Chimerix, Inc. as a drug against cytomegalovirus and adenovirus infections in transplant recipients. Oral brincidofovir was investigated in the Phase III of clinical trials for CMV prophylaxis in stem cell transplants (Marty et al., 2019) but the trials failed due to the toxicity in gastrointestinal tract. Also two other Phase III trials for its use in preventing infection after kidney transplantation and some trials targeted to adenovirus were not successful (Marty et al., 2019; Clinical.trials.gov.; Brincidofovir, 2021). It is speculated that the compound tolerability may be improved by a change in the drug formulation, e.g., by intravenous application. The present plans with brincidofovir are targeted mostly to poxviruses, especially variola virus for the case of a smallpox outbreak. Finally, in June 2021, brincidofovir was approved by FDA as a drug for the treatment of smallpox and is marketed under the brand name Tembexa (FDA, 2021). While the smallpox is eradicated in nature, there is still possibility of variola virus abuse as a biological weapon or its accidental release (FDA, 2021). During Ebola outbreak in 2014 Chimerix also received an FDA approval for investigational applications of brincidofovir for the treatment of Ebola virus disease in patients and approval for the Phase II clinical trials. The trials were subsequently discontinued because of a lack of suitable subjects. Anyway, they highlighted the need to establish better practices for preclinical in vitro and animal screening of therapeutics for potentially emerging epidemic infectious diseases prior to their use in patients (Dunning et al., 2016).

2.1.3 Synthesis of Purine N-2-(Phosphonomethoxy)ethyl (PME) Derivatives

Synthesis of acyclic nucleoside phosphonates of the PME series consists in the base catalysed condensation of a purine or pyrimidine base with a relevant synthetic precursor, i.e., compound containing the whole aliphatic part including a phosphonomethyl arrangement and an appropriate leaving group (mostly tosyl or halogene). 

N-2-(Phosphonomethoxy)ethyl derivatives are synthesized from dialkyl (diethyl or diisopropyl) 2-(chloroethoxy)methylphosphonates. These precursors are accessible by the treatment of trialkyl phosphites with 2-(chloroethoxy)methyl chloride (Holý et al., 1999; Holý et al., 1989) The synthesis of PME (adefovir) according to this procedure is described in Figure 3. Analogous procedures were applied also to the preparation of the cytosstatic guanine derivative PMEG and the series of N₆-substituted PMEDAP, i.e., 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine including 9-[2-
phosphonomethoxy)ethyl]-N<sup>6</sup>-cyclopropyl-2,6-diaminopurine (cPrPMEDAP, the compound which amidate prodrug is used as a veterinary drug rabacfosadine). In these cases condensation of diisopropyl 2-(chloroethoxymethyl)phosphonate is performed with 2-amino-6-chloropurine and the resulting product was further transformed according to Figure 3 (Holý et al., 2001).

Alternative way to 2-(phosphonomethoxy)ethyl derivatives is the reaction of purine bases with dialkyl 2-hydroxyethylphosphonate under Mitsunobu conditions (Chen et al., 1996). Other methods utilize reaction of dialkyl toslyloxymethylphosphonate with an appropriate 9-(2-hydroxyethyl)purine derivative (Figure 4A) or reaction of an analogous purine 2-idoethyl derivative with diethyl hydroxymethylphosphonate (Figure 4B on the example of adefovir). The advantage of the latter one is commercial availability of diethyl hydroxymethylphosphonate (Jones et al., 2019).

### 2.1.4 Adefovir Dipivoxil

Adefovir is active against retroviruses and some types of DNA viruses (Naesens et al., 1994; Holý, 2003; De Clercq and Holý, 2005; De Clercq, 2007). Its activity against HIV and hepatitis B virus consists in the inhibitory effect towards reverse transcriptase.

Synthesis of adefovir prodrug (adefovir dipivoxil, Bis(POM)-PMEA) proceeds from adefovir by the action of chloromethyl pivalate (Figure 3) (Starrett et al., 1992).

Adefovir in the form of bis(pivaloyloxyethyl) ester was being developed originally as anti-HIV agent but the trials were finally discontinued due to the nephrotoxicity at the required daily therapeutic dose 120 mg (Kahn et al., 1999). On the other hand, the efficacy for HBV was found higher when the therapeutic effect was achieved with a ten times lower dose of 10 mg (Izzedine et al., 2004; Fontaine et al., 2005). It enabled development of the compound for the treatment of chronic
hepatitis B in adults, especially for those with lamivudine resistance. In 2002, adefovir dipivoxil was approved by FDA under the trade name Hepsera™. Clinical practice shows that sometimes a higher dose of the drug would have been more efficacious but of course, it is ruled out due to the renal safety (Izzedine et al., 2004; Hézode et al., 2007). In rare cases, it is also reported that prolong treatment with adefovir even in a low dose of 10 mg can cause adefovir-induced osteomalacia, a metabolic bone disease that leads to softening of the bones. It is caused by hypophosphatemia as a result of renal tubular dysfunction (Kim et al., 2013; Park et al., 2018). Clinical use of adefovir dipivoxil started to grow down since the more effective tenofovir disoproxil fumarate and later on, tenofovir alafenamide were approved for HBV (2008 and 2016).
2.1.5 Alternative Prodrugs of Adefovir

Alternative prodrug approaches for adefovir to improve adefovir pharmacokinetics were also investigated, e.g., bis(S-acyl-2-thioethyl esters (SATE-esters) (Benzaria et al., 1996) or substitutes aryl esters, e.g., bis(o-ethoxyphenyl) ester (Figure 3) (Shaw et al., 1997). The bis(tBu-SATE)PMEA has 50-times increased stability in human plasma compared to bis(POM)-PMEA and improved stability in human gastric fluid (Benzaria et al., 1996).

Extensive research was paid also to cyclosaligenyl (cycloSal) phosphonates, i.e., cyclic esters with variously substituted salicyl alcohol and cycloAmb phosphonates (cyclic ester amidates with 2-aminobenzyl alcohol). Investigation of anti-HIV-1 and anti-HIV-2 activity of various cycloSal-PMEA on cell cultures revealed increased antiviral activity compared to the parent PMEA and in parallel, decreased toxicity and decreased stability compared to other types of prodrugs [e.g., SATE or bis(amidates)]. cycloAmb-derivatives had generally increased stability and lower antiviral activity in comparison with cycloSal-PMEAs (Meier et al., 2005). (Figure 5)

An original prodrug technology are HepDirect™ prodrugs. They were developed by Ligand Pharmaceuticals, Inc. with the aim to target adefovir directly to the liver due to specific activation by enzymes overexpressed in the liver tissue (Erion et al., 2004; Tillmann, 2007; Reddy et al., 2008). HepDirect prodrugs are cyclic 1-aryl-1,3-propanyl esters which are susceptible to oxidative cleavage of the ring by a cytochrome P450 isozyme (CYP3A4) (Erion et al., 2004). Chemical synthesis consists in condensation of adefovir with 1-(3-chlorophenyl)-1,3-propanediol. While only cis-(2R,4S)-isomer was found as appropriate prodrug, the synthesis includes stereoselective resolution of racemic intermediate 1-(3-chlorophenyl)-1,3-dihydroxypropane through diastereomeric menthone adducts (Figure 6) (Reddy et al., 2008).

Pradefovir was advanced to Phase II of clinical trials where a 12-fold improvement in the liver/kidney ratio over adefovir dipivoxil has been proven. Further investigation in United States was discontinued when the more effective tenofovir disoproxil fumarate became available. Nevertheless, pradefovir is still in clinical development for Hepatitis B in China. Promising results of their Phase 1b study have been recently published (Zhang et al., 2020).

Besides antiviral effects extensive research was targeted to antibacterial activity of PMEA prodrugs. Studies performed with Bis(POM)PMEA revealed that adefovir upon intracellular conversion into the active metabolite adefovir diphosphate has...
strong activity against adenylate cyclase toxin (ACT) from *Bordetella pertussis*, a causal agent of whooping cough, and both ACT and edema factor (EF) from *Bacillus anthracis*. Various symmetrical amino acid ester based bis(amidates) of PMEA have been developed in our Institute as less toxic and more stable alternatives to bis(POM)PMEA (*Česnek et al.,* 2015; *Břehová et al.,* 2016; *Šmídková et al.,* 2014). The highest activity and optimal pharmacokinetic profile was achieved with bis(isopropyl phenylalanine) amidate pro moiety. Besides, also various base modified PMEA analogues (aza/deaza purine derivatives) were synthesized. One of the most promising ACT inhibitors was found 8-aza-7-deazapurine analogue of PMEA in the form of bis(isopropyl phenylalanine) amidate with IC<sub>50</sub> value 16 nM and substantial selectivity over mammalian adenylate cyclases (*Česnek et al.,* 2018). Synthesis of symmetrical bis(amidates) can be performed from phosphonate diisopropyl esters which are deprotected first with bromotrimethylsilane, followed by condensation with appropriate amino acid ester in the presence of 2,2′-dithiopyridine (Aldrithiol). The reaction scheme is outlined in Figure 7. Extraordinary effect to ACT inhibitory potency has replacement of the adenine moiety with another heterocyclic base able to mimic adenine, namely 2-aminothiazole. These compounds are 5-aryl-4-PME-2-aminothiazoles, 4-aryl-5-PME-2-aminothiazoles and their bis(amidate) prodrugs and phosphono diphosphate analogues (*Břehová et al.,* 2021; *Česnek et al.,* 2022). The most potent inhibitor was diphosphate of 4-(4-(benzylcarbamoyl)phenyl-5-PME-2-aminothiazole (*Figure 7*). It is the most potent ANP-based inhibitor of ACT (IC<sub>50</sub> = 9 nM) and EF (IC<sub>50</sub> = 11.6 nM) known to date.

### 2.1.6 Cytostatic PME Derivatives: PMEG, cPrPMEDAP and Rabacfosadine (GS-9219, VetDC-1101, Tanovea™)

Several years ago, a considerable attention started to be paid to cytostatic 9-[(2-phosphonomethoxy)ethyl] derivatives derived from guanine, 2,6-diaminopurine and N<sup>6</sup>-substituted 2,6-diaminopurine (*Figure 3*). These compounds work via perturbing DNA replication by terminating the growing DNA chain and suppressing the cell growth (at low concentrations) while at higher concentrations they induce apoptotic activity. In cells, they are phosphorylated to diphosphates as active metabolites inhibiting the cell growth due to a potent inhibition of nuclear DNA polymerases. It results in inhibition of DNA synthesis and/or DNA repair (*Kramata et al.,* 1996; *Pisarev et al.,* 1997; *Kramata et al.,* 1998). The most potent compound is PMEG, 9-[(2-phosphonomethoxy)ethyl]guanine; the activities generally increase in the order PMEA < PMEDAP < PMEG. Antitumor effects of PMEG was proven also in animal models in a Sprague–Dawley rat experimental model for T-cell lymphoblastic leukemia/lymphoma (*Rose et al.,* 1990; *Holý,* 2003) but the utility of PMEG for clinical practice is very limited by its poor cellular permeability and toxicity (*Kreider et al.,* 1990; *Rose et al.,* 1990). A fundamental breakthrough was made by the N<sup>6</sup>-substitution of the 6-amino group in 2,6-diamino-9-[(2-phosphonomethoxy)ethyl]purine (PMEDAP) leading to numerous compounds with very promising activity.
Finally, the cyclopropyl derivative, cPrPMEDAP was selected as the lead compound. Its antiproliferative effects were similar to PMEG in vitro, however, in vivo, toxicity of cPrPMEDAP was substantially reduced. In cell cultures, cPrPMEDAP is deaminated to PMEG and then converted to the PMEG-diphosphate—it is evident that cPrPMEDAP acts as an intracellular prodrug of PMEG (Compton et al., 1999; Hatse et al., 1999). The enzyme capable of this conversion was identified as N6-methyl-AMP/dAMP aminohydrolase (Schinkmanová et al., 2006; Schinkmanová et al., 2008).

Nevertheless, cPrPMEDAP, similarly as other ANPs, has a low cellular permeability making its direct clinical use practically impossible and transformation to an appropriate prodrug was necessary. Development of amino acid amidate prodrugs resulted finally in the development of compound GS-9219, the ethyl alaninate prodrug of cPrPMEDAP and concurrently a double prodrug of PMEG. The compound was designed as a cytotoxic agent preferentially targeting lymphoid cells. The compound is prepared from cPrPMEDAP by the action of L-alanine ethyl ester hydrochloride after activation of phosphonic acid residue with Aldrithiol and triphenylphosphine (Cheng et al., 2005; Jansa et al., 2011). The scheme of metabolic conversion of GS-9219 to PMEGpp is outlined in Figure 8. Preclinical trials with dogs with spontaneous non-Hodgkin’s lymphoma proved GS-9219 as generally well tolerated drug with significant antitumor activity warranting its further study in humans (Reiser et al., 2008).

Clinical trials of GS-9219 (Phase I/II) were started in July 2007. The compound was tested in adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and multiple myeloma in twenty leading experimental clinics in United States, Russia and Czech Republic. Despite expectations, 3 years later, in October 2010, the study on GS-9219 has been terminated due to the unacceptable safety profile of the compound (Clinical.trials.gov. GS-9219, 2014). Later on, it was licensed to the veterinary drug company VetDC where the compound was being developed as a veterinary drug against canine lymphoma (VDC-1101, rabacfosadine). In April 2017, it has been approved by FDA as a veterinary drug. The drug is currently marketed by Elanco Animal health under the trade name Tanovea™ (Elanco, 2019).
The whole story has been recently reviewed by De Clercq (De Clercq, 2018).

2.1.7 N-[2-(Phosphonomethoxy)Propyl (PMP) Derivatives Tenofovir and its Prodrugs

Syntheses of enantiomeric N-[2-(phosphonomethoxy)propyl derivatives are based on the condensation of a nucleobase with the appropriate chiral building block. The starting compound for the synthesis of (R)-PMPA (tenofovir) is (R)-2-[bis(2-propyl)phosphonomethoxy]propyl]-p-toluenesulfonate, i.e., "(R)-PMP building block", the compound prepared easily from (R)-1-benzyloxy-2-propanol by multi-step process involving chloromethylation, Arbuzov reaction with triisopropyl phosphite, catalytic hydrogenation and final tosylation (Holý et al., 1995). Condensation of adenine with this precursor followed by deprotection of ester groups gives (R)-9-[2-phosphonomethoxy]propyl]adenine [(R)- PMPA, tenofovir]. For clinical utilization this compound is transformed to the neutral prodrug, bis(isopropoxycarbonyloxyethyl) ester [tenofovir disoproxil, Bis(POC)- (R)-PMPA] and marketed in the form of fumarate salt under the trade name Viread™. The prodrug is synthesized from (R)-PMPA and chloromethyl isopropyl carbonate (Arimilli et al., 1997; Arimilli et al., 1999). The overall scheme of the synthesis of tenofovir and its bis(POC) prodrug is outlined in Figure 9.

Tenofovir is a typical antiretroviral agent acting as a nucleotide reverse transcriptase inhibitor (Srinivas and Fridland, 1998; Suo and Johnson, 1998; Cihlar et al., 2002). In 2001, its bis(isopropoxycarbonyloxyethyl) ester (tenofovir disoproxil fumarate, TDF) was approved for the treatment of HIV infections as one-component drug Viread™ (Srinivas and Fridland, 1998; Lyseng-Williamson, 2005). Current trend in anti-HIV therapy is a combined antiretroviral therapy (cART) consisting in several anti-HIV drugs with different mechanism of action in all-in-one pill. Marketed combinations of TDF are: Truvada (TDF + emtricitabine), Atripla (TDF + emtricitabine + efavirenz), Complera (emtricitabine + rilpivirine) and Striibl (TDF + elvitegravir + cobicistat + emtricitabine) (Gilead, 2022; Deeks and Perry, 2010; De Clercq, E., 2019).

Tenofovir is the most effective, safe and best selling anti-HIV drug. Its special advantages are preventive effects in mother-to-child HIV transmission and relative safety for pregnant women and pediatric patients (Nachega, et al., 2017; Gibb et al., 2012; Siberry et al., 2012; Wang et al., 2013). In 2012, FDA approved Truvada (emtricitabine/tenofovir disoproxil fumarate) as the first drug effective to reduce the risk of HIV transmission to uninfected individuals. Extensive investigations are also carried out in the field of preventive effects of tenofovir containing microbicides. Several clinical studies including daily use of tenofovir vaginal gel or its combination with oral tenofovir are under way in several African countries. Despite an initial enthusiasm from the results of the Caprisa 004 study published in 2010, the following studies (VOICE and FACTS 001) failed due to a failure of the human factor: An adherence in all aspects of the study was too low to confirm effectiveness. The same result was obtained from the FEM-PrEP clinical trial designed to assess prevention of HIV infection with a daily dose of one pill of Truvada (Van Damme et al., 2012; Marrazzo et al., 2015).

Tenofovir has been also investigated as anti-hepatitis B agent and in 2008 approved by FDA for the treatment of chronic...
hepatitis B in adults and pediatric patients 12 years of age and older. Tenofovir disoproxil is more efficacious than previously approved adefovir dipivoxil, and so far there is no reported resistance (Yang et al., 2015; Tillmann and Samuel et al., 2019; de Fraga et al., 2020). Both ANPs (tenofovir and adefovir) act as chain terminators when their metabolites get incorporated into the viral DNA strands while they undergo replication by polymerases or reverse transcriptase. However, recent discoveries showed also an additional immunomodulatory mechanism. Both ANP drugs, (but not nucleoside analogues), induce interferon (IFN)-β in the gastrointestinal tract. Pretreatment of peripheral blood mononuclear cells from HBV patients with these ANPs inhibited LPS-mediated interleukin (IL)-10 production (Murata et al., 2020).

The new prodrug form of tenofovir developed by Gilead Sciences is tenofovir alafenamide (TAF) (De Clercq, 2016; Lee et al., 2005; Birkus et al., 2017). It is preferentially taken up by the lymphatic tissue and, also by liver cells (Birkus et al., 2017). The compound is a typical representative of “ProTides” - aryloxy amino acid phosphoramidates, the technology developed originally by C. McGuigan. “ProTides” are widely used due to optimal pharmacokinetic properties and relatively easy synthesis (Pradere et al., 2014; Heidel and Dowd, 2019). Synthesis of TAF has been described in many patents, including variations of experimental conditions and separation of diastereoisomers (GS-7340 and GS-7339, Figure 10) (Chapman et al., 2001; Ramanathan, 2013). The large-scale synthesis and process for separation of diastereomers by simulated moving bed chromatography (SMBC) is described in ref. (Chapman et al., 2001). The desired isomer was found GS-7340 with anti-HIV-1 activity data about ten-fold higher than GS-7339. For clinical application, the compound is used in the form of hemifumarate (Liu, 2013). For HBV therapy, it is sold under the brand name Vemlidy. At present, TAF has largely replaced TDF in HIV treatments, primarily due to the significant difference in dosage—only 30 vs. 300 mgs, with lower incidence of adverse side effects as well as greatly increased levels of tenofovir inside the virally infected cells (De Clercq, 2016; Sley-Radtke and Yates, 2018; De Clercq, 2019). TAF is also used in various combinations with other antiretroviral drugs (Genvoya, Odefsey, Descovy, Symtuza).

2.2 Current Trends and Future Perspectives

Despite the progress in modern medicine, there will be always need for new biologically active molecules. The reason are emerging infections, arising resistance of many pathogens against standard treatments and increasing number of patients with immunity problems. Many ANPs are active
against serious, life threatening infections still lacking effective treatment e.g., cytomegalovirus and polyomavirus infections (in perinatal patients and transplant or other immunocompromised patients), poxvirus infections and specific herpesvirus infections (e.g., human herpesvirus type 6, HHV-6). All these facts substantiate further investigations in the field which are targeted to the following areas:

1 Compounds from Antonin Holy’s legacy—structures with excellent biological activities still waiting for clinical/preclinical investigations
2 Development of new ANP structures
3 New ANP prodrugs with improved pharmacokinetic properties
4 New targets and new applications

2.2.1 “Old Compounds” Still Waiting for Their Opportunity

During more than 30 years of ANP research at the IOCB, hundreds of structures with excellent biological activities have been synthesized. An integral part of this story was always a personality of Erik De Clercq, Antonin Holy’s friend and collaborator leading all antiviral investigations and also author of many ANP reviews (De Clercq, 2009; De Clercq, 2011; De Clercq, 2013; De Clercq, 2019). Promising structures deserving further investigation are discussed below (Figure 11).

a) FPMP derivatives, i.e., (3-Fluoro-2-phosphonomethoxy)propyl derivatives.

This group of purine ANPs inhibits selectively retroviruses (HIV-1, HIV-2) and also HBV, with no effect towards other DNA viruses. The adenine derivative, (S)-FPMPA has better parameters in vivo compared to PMEA (adefovir) (Balzarini et al., 1991; Jindřich et al., 1993). Anti-HIV activity was also found in both enantiomers of FPMPDAP and FPMPG and some N^6-substituted derivatives of (R)-FPMPDAP (cyclopropyl, propyl, allyl) (Baszczyński and Janeba, 2013).

In the pyrimidine series, no antiviral activity was found but both enantiomers of the thymine derivative 1-[3-fluoro-2-phosphonomethoxy]propyl[thymine (FPMPT) have inhibitory activity towards thymidine phosphorylase, the enzyme playing the key role in the angiogenesis in tumors (Folkman and Shing, 1992; Esteban-Gamboa et al., 2000; Pomeisl et al., 2005). A study carried out on human purine nucleoside phosphorylase (PNP) revealed that the monophosphates derived from both enantiomers of FPMPG are its potent inhibitors. PNP is a purine salvage pathway enzyme catalysing the phosphorolysis of guanosine, inosine and 2′-deoxyguanosine to the corresponding purine base and ribose-1-phosphate or 2′-deoxyribose-1-phosphate, respectively. Pharmacological aspect of PNP inhibition is connected with the treatment of human T-cell proliferative disorders (Votruba et al., 2010)^101.

b) (R)-PMP-derivatives, i.e., (R)-2-(Phosphonomethoxy)propyl derivatives.
The most active antiretroviral compound of this series, 2,6-diaminopurine analogue of tenofovir, (R)-PMPDAP, has not been thus far sufficiently studied, despite the fact that it is 10-fold more potent against HIV-1 compared to tenofovir in vitro and in vivo (Balzarini et al., 1993; Balzarini et al., 1996). It is also strongly active against animal retroviruses, especially feline immunodeficiency virus. Although strong conclusions cannot still be done, some studies revealed slightly positive (Vahlenkamp et al., 1995; Taffin et al., 2015). It is clear that the activity of (R)-PMPDAP in vivo warrants further investigations including synthesis of prodrugs (Krečmerová et al., 2013).

c) “Open-ring” analogues are ANPs having PME-, PMP or HPMP-grouping attached to the position 6 of the 2,4-diaminopyrimidine ring via oxygen atom. They mimic 2,6-diaminopurine ANPs with an open imidazole ring. Their
antiviral activity is essentially identical to that of their parent compounds, including the enantiomeric specificity. It means that (R)-HPMPDAP is a typical anti-DNA virus agent (similarly as cidofovir and other HPMP derivatives) whereas PMEO-DAPy, (R)-PMPO-DAPy a 5-substituted PMEODAPy inhibit retroviruses and HBV (Balzarini et al., 2002; Holy et al., 2002; Hocková et al., 2003; De Clercq et al., 2005; Herman et al., 2010). The most effective antiretroviral compounds are PMEO-5-methyl-DAPy and other 5-substituted PMEO-DAPy derivatives (Hocková et al., 2003). Compound PMEO-DAPy is active not only against retroviruses but also against many DNA viruses, especially herpesviruses affecting immunocompromised patients including those with HIV/AIDS. For this purpose we studied PMEO-DAPy also in the form of various structural types of prodrugs (Krečmerová et al., 2017).

d) HPMP-5-azaC (5-aza analogue of cidofovir), its cyclic form and prodrugs

1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine (HPMP-5-azaC) has been developed as less toxic and more effective alternative to cidofovir. It shows potent and selective activity against all DNA viruses. The activity is comparable to cidofovir concerning herpes viruses (HSV-1, HSV-2) and vaccinia virus, and 2 to 7 times more active against varicella zoster virus (VZV), human cytomegalovirus (HCMV), human herpesvirus type 6 (HHV-6) and adenovirus (Ad2), with generally lower cytotoxicity (Krečmerová et al., 2007a). The prodrug form, hexadecyloxyethyl ester of cyclic HPMP-5-azaC revealed extremely high values of anti-DNA virus activities including imposing selectivity indices on the order of thousands, e.g., 1,160 for herpes simplex virus (HSV-1), ≥5,800 for varicella zoster virus (VZV) or ≥24,600 for human cytomegalovirus (HCMV) (Krečmerová et al., 2007b). Unfortunately, HPMP-5-azaC has rather complicated metabolic profile due to instability of the 5-azacytosine ring and the compound was finally not advanced to clinical investigations (Dračinský et al., 2008; Naesens et al., 2008).

e) HPMPA, HPMPDAP and aza/deaza purine base analogues

(S)-Enantiomers of HPMPA, HPMPDAP and 3-deazaHPMPA are compounds strongly active against DNA viruses, especially herpesviruses but their therapeutic possibilities are so far underexplored. Some of them, e.g., HPMPDAP could be useful for veterinary medicine for their effects towards African swine fever virus (Gil-Fernandez et al., 1987; Holý, 2003). First experiments with HPMPDAP performed in mice were successful. Unfortunately, application of free HPMPDAP to pigs caused serious side effects—the compound was strongly toxic. More research concerning dosing and formulation must be done but it is clear that future investigations need to be performed with prodrug forms (Roels et al., 2013).

Special effort has been also paid to investigation of (S)-HPMPDAP and its prodrugs as anti-pox virus agents. The collaborative project of our institute with Rega Institute and Gilead Sciences had to find a potential drug candidate against poxviruses for the purpose of bioterrorist attack with variola virus (Krečmerová et al., 2010). Large series of cyclic and acyclic HPMPDAP esters were prepared: alkoxyalkyl, POM, 2,2,2-(trifluoro)ethyl, butylsalicyl, and prodrugs based on peptidomimetics. The most potent prodrugs in vitro (tested on vaccinia virus) were the alkoxyalkyl ester derivatives with 50% effective concentrations 400- to 600-fold lower than those of the parent compound. Nevertheless, further in vivo experiments selected finally as the best candidate the acyclic POM ester (Figure 12).

Compounds deserving further investigation are also ANPs active against herpesviruses so far lacking any treatment (e.g., human herpesvirus type 6, HHV-6). HHV-6 takes part in pathogenesis of exanthema subitum (roseola), lymphoproliferative diseases, chronic fatigue syndrome and it is known also as a co-factor of AIDS. It causes severe complications (e.g., encephalitis) in immunocompromised patients. Testing of ANPs for activity against HHV-6 selected 3-deaza-HPMPA and its cyclic form as compounds with the highest activity and selectivity (Reymen et al., 1995). In the series of 8-azapurine analogues, PME-8-azaguaine and (R)-PMP-8-azaguaine are compounds with interesting antiretroviral potency (Holý et al., 1996).

2.2.2 Development of New ANP Structures

New ANP structures modified in the aliphatic side chain and/or in the base moiety are currently being developed in many laboratories. The successful example is besifovir, 9-[2-cyclopropyl-2-(phosphonomethoxy)ethyl]-2-aminopurine. Its prodrug form, besifovir disoproxil is investigated for the HBV treatment in the Phase III of clinical trials (Jung et al., 2020; Kim et al., 2020).

Replacement of a natural nucleobase with another heterocycle has been already mentioned in antibacterial PME-2-aminothiazoles (chapter 1.1.5). Another example is a series of HPMP and PME derivatives bearing a 1,2,4-thiadiazole base moiety which was intended as a cytosine mimic. In contrast to HPMPC, none of these compounds has antiviral activity but they were found potent inhibitors of cysteine dependent enzymes, such as Cathepsine K and glycogen synthase kinase 3β (Pomeislová et al., 2021).

Many side-chain modified ANPs are investigated as potent antiparasitic agents (see chapter 1.2.4.)

2.2.3 New Prodrugs

Prodrugs are pharmacologically inactive compounds which are transformed in vivo to active drugs via metabolic and/or chemical processes occurring in the body. They are developed to optimize pharmacological properties of parent drugs. It is estimated that around 10% of all marketed drugs are prodrugs and their share in the new drug development is continuously increasing (Najjar and Karaman, 2019).

Prodrugs developed for acyclic nucleoside phosphonates can be categorized to the following groups (Pradere et al., 2014; Heidel and Dowd, 2019):
- Symmetrical phosphonate diesters—Alkyl, aryl, acyloxyalkyl (pivaloyloxymethyl, POM), alkoxy carbonyloxyalkyl (isopropoxycarbonyloxymethyl, POC), S-acylthioalkyl (SATE) (Benzaria et al., 1991).
- Asymmetric phosphonate diesters: HepDirect prodrugs (Erion et al., 2004; Reddy et al., 2008) Cyclosaligenyl (cycloSal) phosphonates (cyclic esters with variously substituted salicyl alcohol) (Meier, 2006; Meier and Balzarini, 2006). Despite an enormous amount of work in the area of cycloSal nucleosides, in the field of ANPs, only cycloSal-PMEA and cycloSal-(R)-PMPA were investigated (Meier et al., 2005).
- Phosphonate monoesters—internal cyclic monoesters (esters of cyclic HPMP derivatives, e.g., Figure 2, Figure 12) and monoesters -P(O)(OH)(OR) where R is alkyl, aryl, alkoxyalkyl (e.g., brincidofovir), POM, POC, alkoxy carbonyl.
- Symmetric bisamidates—bisamidates with amino acid esters (e.g., rabacosadine) (De Clercq, 2018).
- Asymmetric mixed ester/amidate/prodrugs—proTides (Cahard et al., 2004; Pradere et al., 2014; Heidel and Dowd, 2019).

Besides improving antiviral activity, cellular uptake and toxicity profile, some types of ANP prodrugs are also reported with respect to influence the antiviral activity spectrum of parent compounds. In the HPMP series, it concerns octadecyloxethyl (ODE) monoesters derived of HPMPA. (S)-HPMPA is active exclusively against most double-stranded DNA viruses but has no in vitro effect against RNA viruses and retroviruses (Holý, 2003; De Clercq and Holý, 2005). Its opposite enantiomer, (R)-HPMPA is completely inactive against all viruses. Despite these facts, HDP and ODE monoesters of (S)-HPMPA were reported as active compounds against HCV (positive sense single-stranded RNA virus). Interestingly, even a prodrug derived from R-enantiomer was active against HCV (Wyles et al., 2009). Moreover, alkoxyalkyl esters of (S)-

![FIGURE 12 | Prodrugs derived from (S)-HPMPDAP as antipox virus agents.](image-url)
HPMPA and its 3-O-methyl derivative, (S)-MPMPA are potent inhibitors of HIV-1 replication (EC\textsubscript{50} value of 7 nM for HDP ester of (S)-HPMPA) (Hostetler et al., 2006; Valiaeva et al., 2006). As expected, remarkable increase in antiviral activity against DNA viruses (HSV-1, HCMV, vaccinia, cowpox and ectromelia virus) was observed in ODE esters of (S)-HPMPA, (S)-HPMPG, (S)-HPMPDAP and its 6-cyclopropylamino analogue (S)-HPMP-cPrDAP. The two most active compounds against HSV-1 were ODE–(S)-HPMPA and ODE–(S)-HPMP with
subnanomolar EC$_{50}$ values in cell cultures (Valiaeva et al., 2009).

Another example of influencing antiviral activity spectrum via synthesis of prodrugs are both enantiomers of 3-fluoro-2-(phosphonomethoxy)propyl]adenine (FPMPA) and other FPMP derivatives. These ANPs are effective antihuman immunodeficiency virus (HIV) agents, but have no activity against a wide range of DNA viruses. The introduction of a diamyl aspartate amidate motif together with a phenyl ester moiety at the phosphorus (de facto a special kind of proTides) not only enhanced antiviral potency against HIV (by a factor up to 1,500), but also against HBV. Interestingly, some of the synthesized compounds exhibited activity against DNA viruses, namely herpes viruses (Luo et al., 2017).

Despite of the huge number of prepared structures and promising in vitro or in vivo studies, only a few of them have been proceeded into clinical trials or clinics (POM, POC, HDP, proTides). It can be attributed to the difficulty of achievement of the right prodrug properties balance, particularly suitable chemical stability at physiological pH, rate of conversion, safety with respect to formed by-products, avoidance of stereoisomers, physical properties (ability to crystallize, solubility), and ability to synthesize substantial quantities. Therefore, search for new structural types of prodrug promoiety is highly desirable.

One such promising strategy is the concept of amino acid prodrugs (Krečmerová, 2017). Single amino acid ester prodrugs were reported in Herdewijn’s group for (S)-HPMPA and its cyclic form (Luo et al., 2018).

Extensive research is paid to prodrugs where the phosphonic acid residue is esterified by a hydroxyl group of hydroxyl amino acids (serine, threonine, tyrosine) which can be used either as single amino acid or as a component of small peptides (dipeptides and tripeptides). To circumvent the problem of the low permeation of peptides through the cell membranes and enzymatic instability in the gastrointestinal tract, structural modifications to form peptidomimetics are the solution. These modifications consist in esterification of a carboxyl group or its transformation. This approach enables wide spectrum of “fine tuning” of pharmacokinetic properties. Additionally, introduction of D-configurated N-terminal amino acids to the dipeptide increases enzymatic stability of the prodrug and its uptake to plasma (Eriksson et al., 2008; Peterson et al., 2011). Extensive research finally showed the best pharmacokinetic profiles in single amino acid prodrugs, especially tyrosine derivatives (Krylov et al., 2013; Zakharova et al., 2011; Williams et al., 2011). Synthesis and structures of peptidomimetic and tyrosine based ANP prodrugs are depicted in Figure 13 on the example of cidofovir. Analogous prodrugs were prepared also from (S)-HPMPA (Zakharova et al., 2011). They have excellent antiviral activity against DNA viruses (HCMV, poxviruses, HSV-1) without any cytotoxicity. Activity data of the cyclic forms are not dependent on stereochemistry at the phosphorus atom (EC$_{50}$ for Rp $>$ Sp). Oral bioavailability in mice was 8-10x higher than that of parent phosphonates (39% vs. 5%) while the tyrosine alkylamide esters had better stability than carboxylate ester derivatives (Zakharova et al., 2011; Krylov et al., 2013).

Significant results have been recently published using tyrosine in synthesis of ANP proTides whose phenyl group is replaced with a modified (S)-tyrosine moiety (Figure 13). This approach applied to tenofovir leads to compounds with substantially increased potency and selectivity index towards HIV as well as HBV compared to tenofovir alafenamide. It is caused by their high cellular uptake and rapid cleavage to the parent drug tenofovir in the target cells (Kalčić et al., 2021).

2.2.4 New Targets, New Applications: Development of ANPs as Antiparasitic Agents

Various purine ANPs have remarkable antiprotozoal activity. The therapeutic potential for the treatment of African trypanosomiasis was identified originally in (S)-HPMPA and (S)-HPMPDAP. The compounds revealed inhibitory effects against Trypanosoma brucei brucei both in vitro and in vivo while inhibitory activity against Trypanosoma congolense was found in PMEDAP (Kaminsky et al., 1994; Kaminsky et al., 1996).

Recent studies selected as the best inhibitors 6-oxopurine ANPs further modified in the side chain (branched nitrogen containing derivatives, bisphosphonates and C-1′-branched ANPs) (Doleželová et al., 2018; Teran, 2020; Doležalová et al., 2021; Kalčić et al., 2021).

Effective inhibitors of Plasmodium HGXPRT are guanine and hypoxanthine ANPs with the following arrangements of the side chain:

a) 2-(Phosphonomethoxy)ethyl derivatives (PEE derivatives; PEEG, PEEHx) (De Jersey et al., 2011; Keough, et al., 2013a).

b) 2-Hydroxy-3-phosphonomethoxypropyl (“iso-HPMP” derivatives) (Krečmerová et al., 2012).

c) Bisphosphonate structures formed by attachment of a second phosphonate group to the ANP scaffold. The most potent was found guanine derivative derived from iso-HPMPG by replacing its hydroxyl with a phosphonomethoxymethyl residue (Figure 14) (Keough, et al., 2013b).

d) N-Branches ANPs (aza-ANPs) containing a trisubstituted nitrogen in the side chain. The most potent inhibitors are 9-[(N-(3-methoxy-3-oxopropyl)-N-(2-phosphonoethyl)]-2-aminoethyl]hypoxanthine and 9-[(N-(2-carboxyethyl)]-N-(2-phosphonoethyl)-2-aminoethyl]guanine (Figure 14). The hypoxanthine derivative exhibits the highest ever reported selectivity for PfHGXPRT compared to human HGPR (Hocková et al., 2012).

e) Thia-ANPs—sulfur bridged acyclic nucleoside analogues, active against Plasmodium enzyme PfHGXPRT in micromolar concentrations and highly selective compared to...
to the human enzyme. Promising inhibitory data were found also in their phosphoramidate prodrugs (Klejch et al., 2019).

Besides above described guanine and hypoxanthine ANP inhibitors, there are also highly effective and selective "ANP-like" inhibitors with unnatural pyrrolidine base moiety (Keough et al., 2018). Purine metabolism was also identified as a ubiquitous factor in the physiology of various other pathogens including Mycobacterium tuberculosis, Mycobacterium smegmatis and other mycobacteria. The purine salvage enzyme HGPRT was found essential for Mycobacterium tuberculosis growth in vitro; however, its precise role in M. tuberculosis physiology is so far unclear. Membrane permeable prodrugs of HGPRT inhibitors arrest the growth of M. tuberculosis and represent potential new antituberculosis compounds (Knejzlík et al., 2020).

3 2-(PHOSPHONOMETHYL) PENTANEDIOIC ACID, 2-PMPA

2-PMPA belongs to the group of phosphorus-based inhibitors of the enzyme glutamate carboxypeptidase II (GCPII) first identified by Jackson and Slusher in 1991 (Jackson et al., 1996; Jackson and Slusher, 2001). When first purified from the brain, Slusher et al. (Slusher et al., 1990) initially named the enzyme NAALADase for
its substrate specificity for N-acetylated-alpha-linked acidic dipeptides; the enzyme has also been called N-acetylaspartylglutamate (NAAG) peptidase, prostate specific membrane antigen (PSMA) and folate hydrolase I (FOLH 1). The enzyme is a zinc metallopeptidase that hydrolyzes terminal glutamate from various substrates. The enzyme is a transmembrane glycoprotein which consists of six domains including the N-terminal cytoplasmic tail, a helical transmembrane region, and four large extracellular domains. The active site of GCPII where 2-PMPA and other competitive inhibitors bind is extracellularly facing (Bařinka et al., 2004).

In the nervous system GCPII converts N-acetylaspartylglutamate (NAAG), one of the most abundant peptides in the brain, to glutamate and N-acetylaspartate while in the jejunum its role also consists in the cleavage of pteroylpolygamma-glutamate to folate and glutamate. In the prostate, GCPII is intensively studied as a both prostate cancer biomarker and a target for radiotherapy (Jones et al., 2020; Zhang et al., 2021). More recently the Slusher team identified that GCPII enzymatic activity is highly upregulated in patient biopsies with inflammatory bowel disease (IBD) and inhibition of this upregulated activity provides therapeutic benefit in preclinical IBD models (Rais et al., 2016; Date et al., 2017; Peters et al., 2019; Peters et al., 2022).

Overexpression of GCPII in the brain leads to reduced NAAG and excess extracellular glutamate which can be pathogenic. Thus, inhibitors of GCPII have been investigated as therapeutic agents for disorders arising from excess glutamatergic transmission (Vornov et al., 2016; Neale and Yamamoto, 2020). Specifically, GCPII inhibitors have been developed as potential therapeutics for the treatment of neuopathic pain (Vornov et al., 2013), peripheral neuropathy (Zhang et al., 2002; Zhang et al., 2006), stroke (Slusher et al., 1999), amyotrophic lateral sclerosis (Ghadge et al., 2003; Tallon et al., 2022), multiple sclerosis (Rahn et al., 2012; Hollinger et al., 2022), schizophrenia (Olszewski et al., 2012), epilepsy (Luszczi et al., 2006), traumatic brain injury (Feng et al., 2011; Gurkoff et al., 2013), addiction (McKinzie et al., 2000; Xi et al., 2010), cognition (Janczura et al., 2013), and perinatal injury (Zhang et al., 2016).

GCPII inhibitors developed so far are polar compounds with structural similarity to NAAG and glutamate. In general, they contain a dicarboxylic acid moiety which binds to the C-terminal glutamate recognition site of GCPII and a zinc-binding group which engages one or both zinc atoms at the active site (Ferraris et al., 2012). The most potent classes belong to phosphonates such as 2-PMPA (Jackson et al., 1996), thiols such as 2-(3-mercaptopropyl)pentane-dioic acid (2-MPPA) (Majer et al., 2003), ureas such as N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-L-leucine (ZJ43) (Olszewski et al., 2017) and (N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]methyl-L-cysteine (DCMC) (Foss et al., 2005), and hydroxamates such as 2-(hydroxycarbamoylmethyl)pentanedioic acid (Stoermer et al., 2003) (Figure 15). Unfortunately, these compounds, with the exception of thiols, have low membrane permeability and oral bioavailability. The thiol inhibitor 2-MPPA advanced to clinical studies (van der Post et al., 2005). It was safe and well tolerated in two Phase 1 studies but subsequent immunological toxicities were observed in chronic GLP primate studies, halting its development. The toxicity was attributed to the thiol nature of the compound, not its GCPII inhibiting activity as it is well documented that thiol-containing drugs can elicit immune hypersensitivity reactions (Jaffe, 1986; Smith et al., 1989; Friedmann et al., 2003).

2-PMPA is one of the most potent GCPII inhibitors identified to date and has been found to have broad and robust neuroprotective and analgesic effects in many preclinical studies conducted by multiple independent laboratories (for review see: Barinka et al., 2012; Vornov et al., 2016; Nonaka et al., 2017). In addition to CNS diseases, GCPII provides metabolic substrates for cancer growth so its inhibition may

![Representative examples of GCPII inhibitors.](frontiersin.org)
provide anticancer activity (Kaittanis et al., 2018; Nguyen et al., 2019). In fact, a recent study showed the therapeutic potential of 2-PMPA in the treatment of glioblastoma (Gao et al., 2021). New opportunities may also arise using 2-PMPA as a nephron-protective strategy in PSMA-targeted prostate cancer radiotherapy (Kratochwil et al., 2015; Chatalic et al., 2016) or use of 2-PMPA as an inhibitor of cytosolic carboxypeptidases (Wang et al., 2020). Despite its proven utility in multiple preclinical models, clinical use of 2-PMPA remains problematic due to its poor pharmacokinetic profile including low cellular uptake, low oral bioavailability, and minimal brain penetration caused by its strongly polar character. Given this, the IOCB and Johns Hopkins Drug Discovery collaborative team decided to focus on synthesizing 2-PMPA prodrugs (Majer et al., 2016; Dash et al., 2019).

2-PMPA prodrugs were synthesised using two different strategies. The first strategy was focused on enhancing its oral bioavailability by covering its charge functionalities using FDA approved promoeities such as pivaloyloxymethyl (POM), alkoxyacylloxylkyl (POC), and 5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL) known to be activated via esterase enzymes expressed in intestines, plasma and liver (van Gelder et al., 2002; Rautio et al., 2008). The second strategy was focused on designing prodrugs for enhanced CNS penetration employing intranasal delivery methods (Rais et al., 2015; Nedelcovych et al., 2017).

To develop orally available 2-PMPA prodrugs, our initial strategy was to cover only the phosphate with hydrophobic moieties (POM, POC) keeping the α—and γ-carboxylates unsubstituted. Unfortunately, these derivatives were chemically unstable and exhibited low permeability. Addition of various α,γ-carboxylic diesters and α-monoesters to the bis-POC/POM derivatives enhanced their chemical stability but these mixed esters were too stable in vivo, resulting in minimal release of 2-PMPA. Iterative medicinal chemistry and pharmacokinetic efforts led to identification of tris-POC-2-PMPA (Figure 16) designed by introducing POC groups on both the phosphonate and the α-carboxylate. (Majer et al., 2016). In mice, oral tris-POC-2-PMPA provided sustained levels of 2-PMPA for over 4 h, with >20 fold enhancement in total 2-PMPA exposure when compared to orally administered 2-PMPA at a molar equivalent dose. The substantial oral exposure was subsequently confirmed in a beagle dog. The results provided the first example of orally bioavailable prodrugs of phosphonate based GCPII inhibitors and provided a roadmap for the design and development of other prodrugs from this potent class of compounds.

Encouraging results with tris-POC-2-PMPA stimulated further efforts in investigation and optimization of 2-PMPA prodrugs which resulted in the synthesis of (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL) derivatives (Figure 17). ODOL promoieties have been applied to enhance oral absorption of several FDA-approved drugs including olmesartan and azilsartan medoxomil (Brousil and Burke, 2003; Babu et al., 2009; Garaga et al., 2015). 2-PMPA derivatives masked with two, three, or four ODOL groups were synthesised and evaluated for in vitro stability and in vivo pharmacokinetics in mice and dogs (Dash et al., 2019). All prodrugs were found to be moderately stable at physiological pH, but rapidly hydrolysed in plasma and liver microsomes by the action of ubiquitous esterase enzymes. Like tris-POC-2-PMPA, ODOL prodrugs increased 2-PMPA plasma and brain exposures. The tetra-ODOL-2-PMPA prodrug was the best and demonstrated a remarkable 80-fold enhancement in exposure versus oral 2-PMPA. In dogs, relative to orally administered 2-PMPA, the compound delivered a 44-fold enhanced 2-PMPA plasma exposure.

Unfortunately, while high plasma exposures were achieved with orally administered tris-POC-2-PMPA and tetra-ODOL-2-PMPA, the brain/plasma ratio remained low (<5%) due to their rapid conversion by plasma and liver enzymes. To further enhance brain exposures and brain/plasma ratio for use as a CNS therapeutic, we designed additional 2-PMPA prodrugs for intranasal (IN) administration by masking its γ-carboxylate. When compared to IN delivery 2-PMPA at 1 h post dose, γ-(4-acetoxybenzyl)-2-PMPA [Compound 1 in: Nedelcovych et al., 2017 and Figure 16] resulted in enhanced delivery of 2-PMPA delivery to both plasma (4.1-fold) and brain (11-fold). The combined produg and IN delivery strategies are currently being employed with other inhibitors in an attempt to identify a clinically viable candidate.

The synthesis of tetra-ODOL-2-PMPA from 2-PMPA dibenzyl diethyl ester utilizes different reactivity of carboxylic and phosphonate esters towards bromotrimethylsilane. Carboxylic benzyl esters are
deprotected first by catalytic hydrogenation and replaced by the ODOL moieties. The following deprotection of phosphonate ethyl esters with bromotrimethylsilane proceeds with the preservation of ODOL esters in the carboxylic groups which enables subsequent esterification of the phosphonate groups with 4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one (Figure 17).

**CONCLUSION**

Phosphonates have unique and irreplaceable position in drug design and development due to their increased metabolic stability and bioisostericity with phosphates. The ability to interact with various enzymes and influence diverse metabolic pathways in the body is a benefit usable practically in all areas of medicine. The main research challenges on their way from chemistry to clinics are formulation strategies and/or transformation to prodrugs due to their low bioavailability related to a strongly polar character.

**AUTHOR CONTRIBUTIONS**

All authors contributed to manuscript preparation and writing. MK conducted extensive literature searches, designed the figures and structures and wrote the main part of the manuscript text, with primary responsibility for the ANP sections. BS and RR had primary responsibility for the text related to 2-PMPA prodrugs which included biological data obtained in their laboratory. BS, RR, and PM all performed final revision of the manuscript.

**FUNDING**

This work was supported by the Subvention for Development of Research Organisation RVO 61388963 and by the Czech National Node to the European Infrastructure for Translational Medicine EATRIS-CZ, Grant No. LM2018133 and by NIH P30MH075673, R01NS113140, R01AG068130, and the Crohn’s and Colitis Foundation.
REFERENCES

Alcamo, A. M., Wolf, M. S., Alessi, L. J., Chong, H. J., Green, M., and Williams, J. V. (2020). Successful Use of Cidofovir in an Immunocompetent Child with Severe Adenoviral Sepsis. *Pediatrics* 145 (1), 1632. doi:10.1542/peds.2019-1632

Andreï, G., and Snoeck, R. (2010). Cidofovir Activity against Poxvirus Infections. *Viruses-Basel* 2 (12), 2803–2830. doi:10.3390/v21220803

Andreï, G., Topalis, D., De Schutter, T., and Snoeck, R. (2015). Insights into the Mechanism of Action of Cidofovir and Other Acyclic Nucleoside Phosphonates against Polyoma- and Papillomaviruses and Non-viral Induced Neoplasia. *Antivir. Res.* 114, 21–46. doi:10.1016/j.antiviral.2014.10.012

Arimilli, M. N., Dougherty, J., Cundy, K. C., and Bischofberger, N. (1999). Orally Bioavailable Acyclic Nucleoside Phosphonate Prodrugs: Adefovir Dipivoxil and bis(POC)PMPA. *Adv. Antivir. Drug Res.* 3, 69–91. doi:10.1016/S1075-8593(99)80004-5

Arimilli, M. N., Kim, C. U., Mulato, A., Oliyai, R., Shaw, J. P., et al. (1997). Synthesis, *In Vitro* Biological Evaluation and Oral Bioavailability of 9-[(2-phosphonomethoxy)propyl]adenine (PMPA) Prodrugs. *Antivir. Chem. Chemother.* 8 (6), 557–564. doi:10.1177/095632029700800610

Babu, K. S., Reddy, M. S., Tagore, A. R., Reddy, G. S., Sebastian, S., Varma, M. S., et al. (2009). Efficient Synthesis of Olsensartan Medoxomil, an Antihypertensive Drug. *Syst. Chem. Commun.* 39 (2), 291–298. doi:10.1016/j.ijsonl.80372558

Balzarini, J., Aquaro, S., Perno, C. F., Vittinghoff, M., Holý, A., and De Clercq, E. (1995). Clinical Research and Treatment of Adenoviral Infections. *Adv. Antivir. Drug Res.* 21, 2354–2506. doi:10.1016/0065-2703(95)2546. doi:10.1002/cmdc.201600439

Bhat, D. R., Muskhelishvili, M., and Kasaian, A. (2021). Acyclic Nucleoside Phosphonates with 2-aminothiazole Base as Potent Inhibitors of Adenylate Cyclase from Bordetella Pertussis. *ChemMedChem* 10 (8), 1351–1364. doi:10.1002/cmdc.201500183

Cesnak, M., Šarfánek, M., Dračinský, M., Touitouová, E., Mertlíková-Kaiserová, H., Hayes, M. P., et al. (2022). Halogen-Dance-Based Synthesis of Phosphonomethoxyethyl (PME) Substituted 2-Aminoazoles as Potent Inhibitors of Bacterial Adenylate Cyclases. *ChemMedChem* 17 (1), e202100568. doi:10.1002/cmdc.202100568

Cesnak, M., Šarfánek, M., Dračinský, M., Brust, T. F., et al. (2015). Bisamidate Prodrugs of 2-substituted 9-2-(phosphonomethoxy)ethyl Adenine (PMEA, Adefovir) as Selective Inhibitors of Adenylate Cyclase Toxin from Bordetella Pertussis. *ChemMedChem* 10 (8), 1351–1364. doi:10.1002/cmdc.201500183

Chapman, H., Kernan, M., Prisbe, E., Rohloff, J., Sparacino, M., Terhorst, T., et al. (2001). Practical Synthesis, Separation, and Stereochemochemical Assignment of the PMPA Pro-drug GS-7340. *Nucleosides, Nucleotides, Nucleic Acids* 20 (4–7), 621–628. doi:10.1081/NN-100102338

Chatalic, K. L. S., Heskamp, S., Konijnenberg, M., Molkenboer-Kuenen, J. D. M., Franssen, G. M., Claesen-van Groningen, M. C., et al. (2016). Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-specific Membrane Antigen-Targeted Theranostic Agent. *Theranostics* 6 (6), 849–861. doi:10.7150/thno.14744

Chen, W., Flavin, M. T., Filler, R., and Xu, Z. Q. (1996). An Improved Synthesis of 9-[(2-dithyosphonomethoxy)ethyl]adenine and its Analogues with Other Purine Bases Utilizing the Mitsunobu Reaction. *Nucleosides Nucleotides Nucleic Acids* 15 (11–12), 1771–1778. doi:10.1080/01492918(96)08002731

Cheng, X., Cook, G. P., and Desai, M. M. (2005). Phosphonates, Monophosphonamidates Bisphosphonates for the Treatment of Viral Diseases. U.S. Patent No WO2005066189 A1. Foster City, CA, United States: Gilead Sciences, Inc. Publication date 21.07.2005.

Cihlar, T., Birkus, G., Greenwald, D. E., and Hitchcock, M. J. M. (2002). Tenofovir Exhibits Low Cytoxicity in Various Human Cell Types: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors. *Antivir. Res.* 54 (1–3), 37–45. doi:10.1016/S0166-3542(01)00210-8

Clinical.trials.gov (2021). Brincidofovir. Available at: https://clinicaltrials.gov/ct2/results?term=brincidofovir&Search=Search.

Clinical.trials.gov (2014). GS-9219. Available at: http://clinicaltrials.gov/ct2/results?term=GS-9219&Search=Search.

Compton, M. L., Toole, J. J., and Paborsky, L. R. (1999). 9-(2-Phosphonomethoxyethyl)-N-6-Cyclopropyl-2,6-Diaminopurine (Cpr-PMEDAP) as a Prodrug of 9-[(2-Phosphonomethoxy)ethyl]guanine (PMEG). *Biochem. Pharmacol.* 58 (4), 709–714. doi:10.1016/S0006-2952(99)01138-0

Cundy, K. C. (1999). Clinical Pharmacokinetics of the Antiviral Nucleotide Analogue Cidofovir and Adefovir. *Clin. Pharmacokinet.* 36 (2), 127–143. doi:10.2165/00003088-199936020-00004

Dash, R. P., Tichy, T., Veeravalli, V., Lam, J., Alt, J., Wu, Y., et al. (2019). Enhanced Oral Bioavailability of 2-(Phosphonomethyl)-Pentanedioic Acid (2-PMPA) from its (5-Methyl-2-Oxo-1,3-Dioxo-4-Yl)methyl (ODOL)-Based Prodrugs. *Mol. Pharm.* 16 (10), 4292–4301. doi:10.1021/acs.molpharmaceut.9b00637

Date, A. A., Rais, R., Babu, T., Ortiz, J., Kanvinde, P., Thomas, A. G., et al. (2017). Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors. *Antimicrob. Agents Chemother.* 60 (1), 316–322. doi:10.1128/AAC.01834-15

Břehová, P., Chaloupček, E., Cesnek, M., Škartel, J., Dračinský, M., Touitouová, E., et al. (2021). Acyclic Nucleoside Phosphonates with 2-aminothiazole Base as Inhibitors of Bacterial and Mammalian Adenylate Cyclases. *Eur. J. Med. Chem.* 222, 113581. doi:10.1016/j.ejmech.2021.113581

Břehová, P., Šmídková, M., Škartel, J., Dračinský, M., Mertlíková-Kaiserová, H., Velasquez, M. P. S., et al. (2016). Design and Synthesis of Fluorescent Acyclic Nucleoside Phosphonates as Potent Inhibitors of Bacterial Adenylate Cyclases. *ChemMedChem* 11 (2), 2354–2546. doi:10.1002/cmdc.201600439

Brousil, J. A., and Burke, J. M. J. C. (2003). Olsensartan Medoxomil: an Angiotensin II Receptor Blocker. *Clin. Ther.* 25 (4), 1041–1055. doi:S0149-2918(01)80066-8

Cahard, D., McGuigan, C., and Balzarini, J. (2004). Arylxylo Phosphoramidate Triesters as Pro-tides. *Mini Rev. Med. Chem.* 4 (4), 371–378. doi:10.2174/13895570477703463

Krečmerová et al. Phosphonates and Phosphonate Prodrugs

Frontiers in Chemistry | www.frontiersin.org May 2022 Volume 10 Article 889737 21
Zhang, W., Slusher, B., Murakawa, Y., Wozniak, K. M., Tsukamoto, T., Jackson, P., et al. (2002). A. GCPII (NAALADase) Inhibition Prevents Long-Term Diabetic Neuropathy in Type 1 Diabetic BB/Wor Rats. *J. Neurol. Sci.* 194 (1), 21–28. doi:10.1016/S0022-510X(01)00670-0

Zhang, Z., Bassam, B., Thomas, A. G., Williams, M., Liu, J. H., Nance, E., et al. (2016). Maternal Inflammation Leads to Impaired Glutamate Homeostasis and Up-Regulation of Glutamate Carboxypeptidase II in Activated Microglia in the Fetal/newborn Rabbit Brain. *Neurobiol. Dis.* 94, 116–128. doi:10.1016/j.nbd.2016.06.010

**Conflict of Interest:** BS and RR are listed as inventors on a Johns Hopkins patent applications covering the use of GCPII inhibitors as IBD therapeutics (PCT/US 15/044,025) and shielding agents for prostate cancer radiotherapy (US 16/604,663). BS, RR, and PM are listed as inventors on several composition of matter GCPII patent applications (US 21/015,732; US 62/423,839; US 62/484,219). This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Krečmerová, Majer, Rais and Slusher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
| GLOSSARY |
|-----------------|----------------------------------|
| ACT | adenylate cyclase toxin |
| ANP | acyclic nucleoside phosphonate |
| cPrPMEDAP | 9-[(2-phosphonomethoxy)ethyl]-N⁶-cyclopropyl-2,6-diaminopurine |
| DAPy | 2,4-diaminopyrimidine |
| DCMC | (N-[(N-[(S)-1,3-dicarboxypropyl]carbamoyl]methyl-L-cysteine |
| DIAD | diisopropyl azodicarboxylate |
| EF | edema factor |
| GCPII | glutamate carboxypeptidase II |
| FPMP | 3-fluoro-2-(phosphonomethoxy)propyl |
| HBV | hepatitis B virus |
| HCMV | human cytomegalovirus |
| HCV | hepatitis C virus |
| HDP | hexadecyloxypropyl |
| HHV-6 | human herpesvirus type 6 |
| HPMP | 3-hydroxy-2-(phosphonomethoxy)propyl |
| HPMPA | 9-3-hydroxy-2-(phosphonomethoxy)propyl]adenine |
| HPMPC | 1-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine |
| HPMPDAP | 9-3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine |
| HSV-1 | herpes simplex virus type 1 |
| IBD | inflammatory bowel disease |
| LPS | lipopolysaccharide |
| 2-MPPA | 2-(3-mercaptopropyl)pentane-dioic acid |
| NAAG | N-acetylaspartylglutamate |
| ODE | octadecyloxyethyl |
| PEE | 2-(phosphonoethoxy)ethyl |
| PfHGPRT | Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase |
| PME | 2-(phosphonomethoxy)ethyl |
| PMEA | 9-[2-(phosphonomethoxy)ethyl]adenine |
| PMEDAP | 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine |
| PMEG | 9-[2-(phosphonomethoxy)ethyl]guanine |
| PMEO-DAPy | 6-2-(phosphonomethoxy)ethoxy]-2,4-diaminopyrimidine |
| PMP | 2-(phosphonomethoxy)propyl |
| PMPA | 9-[2-(phosphonomethoxy)propyl]adenine |
| 2-PMPA | 2-(phosphonomethyl) pentanedioic acid |
| POM | pivaloyloxymethyl |
| POC | isoproxyoxycarbonyloxymethyl |
| PRTase | phosphoribosyltransferase |
| PSMA | prostate specific membrane antigen |
| ODOL | (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl |
| SATE | S-acyl-2-thioethy |
| TDF | tenofovir disoprovir fumarate |